...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Top-Line Results for Phase 3 BETonMACE Cardio Outcomes Trial were Announced September 30, 2019

Free
Message: BETonMACE Enrollment

Bear,

Thanks for the reading assignement. I do recall now that BETonMACE did exclude patients with ALT/AST levels greater than 1.5 the upper limits.

Interesting to see where the liver research takes us. This opens up a whole new market.

CD

Share
New Message
Please login to post a reply